市传内地第二轮「4+7」仿制药全国招标将开启
据内地《金融界》报道,上周五晚上开始於内地一份「4+7」(4个直辖市加上7个省会城市)药品集中采购座谈会纪要在业内流传,并引起了业内的高度关注。还有一份内蒙古兴安盟用55种辅助用药的消息在业内流传,具有风向标意义的这个举动同样引起了医药界的高度关注。
座谈会纪要显示,7月12日下午国家医保局在上海召集相关部门和仿制药企业举行座谈。这个消息尚未得到官方的正式确认,但从企业处得到了印证。座谈会纪要透露出的信息,与此前市场传闻有较大出入。此前市场传闻「4+7」城市要全面铺开,在去年首次招标的25品种之上大量增加新的品种。
纪要透露的信息是,第二轮招标品种仍是先前的25个,但招标的范围要从「4+7」城市拓展到全国所有省份及地区,包括全部地区的公立医院、定点民营医院、军队医院,并拿出全国用量的70%来招标。这个变化,给25个品种以外的药企一丝喘息的机会,也给25个品种之内的药企扩大供给量及重新上车的机会。
根据4+7药品集中采购座谈会纪要,第二轮招标计划中的一个重要内容,是将在全国执行3家仿制药通过一致性评价後不得采购未过评药品的政策,不但不采购,而且不报销。原本首轮4+7药品集中采购後,一些仿制药企业出现了观望等待的态度,现今国家医保局明确严格执行仿制药一致性评价政策,不去做一致性评价就没有市场机会了,仿制药企业会加快一致性评价的进程。(wl/u)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.